Published in:
01-10-2020 | Coronavirus | Original Communication
COVID-19 in teriflunomide-treated patients with multiple sclerosis
Authors:
Amir Hadi Maghzi, Maria K. Houtchens, Paolo Preziosa, Carolina Ionete, Biljana D. Beretich, James M. Stankiewicz, Shahamat Tauhid, Ann Cabot, Idanis Berriosmorales, Tamara H. W. Schwartz, Jacob A. Sloane, Mark S. Freedman, Massimo Filippi, Howard L. Weiner, Rohit Bakshi
Published in:
Journal of Neurology
|
Issue 10/2020
Login to get access
Abstract
The outbreak of a severe acute respiratory syndrome caused by a novel coronavirus (COVID-19), has raised health concerns for patients with multiple sclerosis (MS) who are commonly on long-term immunotherapies. Managing MS during the pandemic remains challenging with little published experience and no evidence-based guidelines. We present five teriflunomide-treated patients with MS who subsequently developed active COVID-19 infection. The patients continued teriflunomide therapy and had self-limiting infection, without relapse of their MS. These observations have implications for the management of MS in the setting of the COVID-19 pandemic.